» Articles » PMID: 16189080

Aptamers That Preferentially Bind Type IVB Pili and Inhibit Human Monocytic-cell Invasion by Salmonella Enterica Serovar Typhi

Overview
Specialty Pharmacology
Date 2005 Sep 29
PMID 16189080
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Salmonella enterica serovar Typhi is an important pathogen exclusively for humans and causes typhoid or enteric fever. It has been shown that type IVB pili, encoded by the S. enterica serovar Typhi pil operon located in Salmonella pathogenicity island 7, are important in the pathogenic process. In this study, by using both an adhesion-invasion assay and fluorescence quantitative PCR analysis, we demonstrated that the entry of type IVB piliated S. enterica serovar Typhi A21-6 (pil(+) Km(r)) into human THP-1 monocytic cells was greater than that of a nonpiliated S. enterica serovar Typhi pilS::Km(r) (pil mutant) strain. We have applied a systematic evolution of ligands by exponential enrichment approach to select oligonucleotides (aptamers) as ligands that specifically bind to type IVB pili. Using this approach, we identified a high-affinity single-stranded RNA aptamer (S-PS(8.4)) as a type IVB pilus-specific ligand and further found that the selected aptamer (S-PS(8.4)) could significantly inhibit the entry of the piliated strain (but not that of the nonpiliated strain) into human THP-1 cells. The binding affinities between aptamers and pre-PilS (structural protein of type IVB pili) were determined by nitrocellulose filter-binding assays, and the K(d) value was determined to be 8.56 nM for the S-PS(8.4) aptamer alone. As an example of an aptamer against type IVB pili of S. enterica serovar Typhi, the aptamer S-PS(8.4) can serve as a tool for analysis of bacterial type IVB pilus-host cell interactions and may yield information for the development of putative new drugs against S. enterica serovar Typhi bacterial infections, useful both in prevention of infection and in therapeutic treatment.

Citing Articles

Aptamers: precision tools for diagnosing and treating infectious diseases.

Sujith S, Naresh R, Srivisanth B, Sajeevan A, Rajaramon S, David H Front Cell Infect Microbiol. 2024; 14:1402932.

PMID: 39386170 PMC: 11461471. DOI: 10.3389/fcimb.2024.1402932.


Novel Aptamer Strategies in Combating Bacterial Infections: From Diagnostics to Therapeutics.

Ye Z, Chen H, Weinans H, van der Wal B, Rios J Pharmaceutics. 2024; 16(9).

PMID: 39339177 PMC: 11435160. DOI: 10.3390/pharmaceutics16091140.


RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens.

Kola N, Patel D, Thakur A Methods Mol Biol. 2024; 2813:321-370.

PMID: 38888787 DOI: 10.1007/978-1-0716-3890-3_21.


Aptamers: A Cutting-Edge Approach for Gram-Negative Bacterial Pathogen Identification.

Cordova-Espinoza M, Gonzalez-Vazquez R, Barron-Fattel R, Gonzalez-Vazquez R, Antonio Vargas-Hernandez M, Albores-Mendez E Int J Mol Sci. 2024; 25(2).

PMID: 38279257 PMC: 10817072. DOI: 10.3390/ijms25021257.


From to Typhi: The Fascinating Journey of the Virulence and Pathogenicity of Typhi.

Chatterjee R, Roy Chowdhury A, Mukherjee D, Chakravortty D ACS Omega. 2023; 8(29):25674-25697.

PMID: 37521659 PMC: 10373206. DOI: 10.1021/acsomega.3c02386.


References
1.
Meli M, Vergne J, Decout J, Maurel M . Adenine-aptamer complexes: a bipartite RNA site that binds the adenine nucleic base. J Biol Chem. 2001; 277(3):2104-11. DOI: 10.1074/jbc.M107130200. View

2.
Hicke B, Marion C, Chang Y, Gould T, Lynott C, Parma D . Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem. 2001; 276(52):48644-54. DOI: 10.1074/jbc.M104651200. View

3.
Proske D, Hofliger M, Soll R, Beck-Sickinger A, Famulok M . A Y2 receptor mimetic aptamer directed against neuropeptide Y. J Biol Chem. 2002; 277(13):11416-22. DOI: 10.1074/jbc.M109752200. View

4.
Ulrich H, Magdesian M, Alves M, Colli W . In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem. 2002; 277(23):20756-62. DOI: 10.1074/jbc.M111859200. View

5.
Joshi P, Prasad V . Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol. 2002; 76(13):6545-57. PMC: 136251. DOI: 10.1128/jvi.76.13.6545-6557.2002. View